Abstract

Rifamycins are mainstay agents in treatment of many widespread diseases, but how an improved rifamycin producer can be created is still incompletely understood. Here, we describe a comparative genomic approach to investigate the mutational patterns introduced by the classical mutate-and-screen method in the genome of an improved rifamycin producer. Comparing the genome of the rifamycin B overproducer Amycolatopsis mediterranei HP-130 with those of the reference strains A. mediterranei S699 and U32, we identified 250 variations, affecting 227 coding sequences (CDS), 109 of which were HP-130-specific since they were absent in both S699 and U32. Mutational and transcriptional patterns indicated a series of genomic manipulations that not only proved the causative effect of mutB2 (coding for methylmalonyl-CoA mutase large subunit) and argS2 (coding for arginyl tRNA synthetase) mutations on the overproduction of rifamycin, but also constituted a rational strategy to genetically engineer a reference strain into an overproducer.

Autore Pugliese

• Siculella Luisa , Alifano Pietro , De Benedetto Giuseppe, Egidio , Damiano Fabrizio

Tutti gli autori

• Peano C. , Damiano F. , Forcato M. , Pietrelli A. , Palumbo C. , Corti G. , Siculella L. , Fuligni F. , Tagliazucchi G.M. , De Benedetto G.E. , Bicciato S. , De Bellis G. , Alifano P.

Titolo volume/Rivista

METABOLIC ENGINEERING

Anno di pubblicazione

2014

ISSN

1096-7176

ISBN

Non Disponibile

Numero di citazioni Wos

7

Ultimo Aggiornamento Citazioni

28/04/2018

Numero di citazioni Scopus

9

Ultimo Aggiornamento Citazioni

28/04/2018

Settori ERC

Non Disponibile

Codici ASJC

Non Disponibile